April 1, 2024 02:36 PM EDT

BMS' confirmatory trial of Krazati hits primary endpoint following 2022 accelerated approval

Bristol Myers Squibb scored a confirmatory trial win for Krazati, the KRAS inhibitor it picked up earlier this year through its $4.8 billion

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BM­S' con­fir­ma­to­ry tri­al of Kraza­ti hits pri­ma­ry end­point fol­low­ing 2022 ac­cel­er­at­ed ap­proval